Satellos Bioscience releases investor presentation on Duchenne muscular dystrophy program
MSLE•MSLE•MSLE•MSLE•The presentation highlights two Phase 2 studies:
Phase 1b data in five adults cited 2x grip-strength increases, a 5.8% rise in predicted FVC, and biomarker shifts within 15 days.
Satellos Bioscience published an investor presentation outlining its muscle-regeneration strategy for Duchenne muscular dystrophy built around forazapadin (SAT-3247).
The program is positioned as an oral, once-daily small molecule designed to restore muscle stem cell polarity via AAK1 inhibition.
